Roe James M, Jagust William J, Landau Susan M, Harrison Theresa M, Grydeland Håkon, Slivka Maksim, Alatorre-Warren José-Luis, Garrido Pablo F, Sørensen Øystein, Grødem Edvard O S, Ward Tyler J, Leonardsen Esten H, Fladby Tormod, Bjørnerud Atle, Walhovd Kristine B, Fjell Anders M, Vidal-Piñeiro Didac, Wang Yunpeng
Center for Lifespan Changes in Brain and Cognition (LCBC), Department of Psychology, University of Oslo, Oslo, Norway.
Computational Radiology and Artificial Intelligence, Department of Radiology and Nuclear Medicine, Oslo University Hospital, Oslo, Norway.
bioRxiv. 2025 Aug 20:2025.08.14.670398. doi: 10.1101/2025.08.14.670398.
Alzheimer's disease (AD) is now defined based on its underlying brain pathology, with the presence of amyloid (Aβ) plaques at high enough levels sufficient to warrant a diagnosis in the absence of cognitive symptoms. High levels of PET-detectable Aβ are widely thought to be the first imaging marker, with structural brain changes detectable on MRI scans thought to occur later. We combined 4570 longitudinal MRIs and 1684 Aβ PET scans from three cognitively healthy cohorts to test the difference in cortical thickness and its change between those that subsequently converted to be Aβ-positive or stayed Aβ-negative, using MRIs acquired exclusively in the years before conversion. We found those that subsequently developed elevated Aβ levels show both thicker cortex and less cortical thinning, even when the last MRI used to estimate their thickness trajectories was acquired at least seven years before conversion. Many effects remained when accounting for quantitative Aβ levels, suggesting some cortical thickness effects may be partly independent of Aβ. Differences in cortical thickness and its change between converters and Aβ-negative individuals showed moderate alignment with patterns of Aβ deposition, and the timing of thickness changes tracked the temporal progression of Aβ accumulation. Thus, if amyloid is AD, we show that high levels of PET-detectable amyloid are not the first imaging marker of AD, as cortical thickness changes can be traced years before pathological amyloid. This has implications for understanding the sequence of events leading up to the earliest stages of AD.
阿尔茨海默病(AD)现在是根据其潜在的脑病理学来定义的,即淀粉样蛋白(Aβ)斑块的存在水平足够高,在没有认知症状的情况下足以做出诊断。人们普遍认为,PET可检测到的高水平Aβ是首个成像标志物,而MRI扫描中可检测到的脑结构变化则被认为发生在较晚阶段。我们结合了来自三个认知健康队列的4570份纵向MRI和1684份Aβ PET扫描,以测试随后转变为Aβ阳性或保持Aβ阴性的个体之间皮质厚度及其变化的差异,使用的是在转变前几年专门获取的MRI。我们发现,那些随后Aβ水平升高的个体不仅皮质更厚,而且皮质变薄程度更小,即使在用于估计其厚度轨迹的最后一次MRI扫描是在转变前至少七年获取的情况下也是如此。在考虑定量Aβ水平时,许多效应仍然存在,这表明一些皮质厚度效应可能部分独立于Aβ。转变者和Aβ阴性个体之间皮质厚度及其变化的差异与Aβ沉积模式有适度的一致性,厚度变化的时间跟踪了Aβ积累的时间进程。因此,如果淀粉样蛋白就是AD,我们表明PET可检测到的高水平淀粉样蛋白不是AD的首个成像标志物,因为皮质厚度变化可以在病理性淀粉样蛋白出现前数年就被追踪到。这对于理解导致AD最早阶段的事件顺序具有重要意义。